DGX

Quest Diagnostics Inc. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This filing covers the quarterly period ended March 31, 2026. Quest Diagnostics operates primarily through its Diagnostic Information Services (DIS) segment, which accounts for over 95% of net revenues, providing laboratory testing and diagnostic insights. The company also operates a Diagnostic Solutions (DS) segment focused on risk assessment and healthcare IT. As of April 15, 2026, there were approximately 110.7 million shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 9.2% year-over-year, driven by a 9.4% increase in DIS revenues. This was primarily due to organic volume growth of 10.8%, significantly boosted by new relationships with Corewell Health and Fresenius Medical Care.
• Pricing Pressure: Revenue per requisition decreased 1.3%, attributed to the business mix of new partners involving a higher proportion of routine tests. Excluding these partners, revenue per requisition increased approximately 2.5%.
• Profitability: Operating income rose 15.5% to $399 million. Cost of services increased 9.2% due to higher compensation and supply costs, partially offset by savings from the "Invigorate" productivity program.
• Acquisition Activity: The company completed a transaction in January 2026 to form a joint venture with Corewell Health in Michigan, contributing $38 million in cash consideration and consolidating the entity.
• Restructuring: Pre-tax restructuring charges were $7 million in Q1 2026, down from $11 million in Q1 2025, primarily related to employee separation costs.

Guidance, Outlook, and Risks

• Capital Allocation: The Board authorized an additional $1 billion share repurchase program in February 2026, with $1.4 billion remaining available. No shares were repurchased in Q1 2026. The quarterly dividend was increased to $0.86 per share (from $0.80 in 2025).
• Investment Outlook: The company estimates capital expenditures of approximately $550 million for 2026 to support laboratory automation and IT infrastructure, including "Project Nova" for order-to-cash modernization.
• Liquidity: The company maintains $1.3 billion in available borrowing capacity across its credit facilities. Cash and cash equivalents were $393 million as of March 31, 2026.
• Risks and Contingencies:
  • Legal Proceedings: Ongoing litigation includes the AMCA data security incident class actions, ERISA plan lawsuits, and various government investigations regarding billing practices. Reserves for legal matters totaled $20 million.
  • Professional Liability: Reserves for general and professional liability claims (including Irish pap smear screening claims) totaled $173 million.
  • Market Risk: The company uses interest rate swaps to manage exposure, with $1.8 billion in notional amounts outstanding.

Investor Verification Checklist

• Volume vs. Price Mix: Verify the sustainability of the 10.8% organic volume growth against the 1.3% decline in revenue per requisition, specifically analyzing the long-term margin impact of the Corewell and Fresenius partnerships.
• Restructuring Progress: Monitor the execution of the "Invigorate" program to ensure the targeted 3% annual cost savings materialize to offset inflationary labor costs.
• Legal Exposure: Review updates on the AMCA data security incident and Irish pap smear litigation, as reserve adequacy ($173 million) relies on actuarial estimates subject to uncertainty.
• Debt Maturities: Confirm the repayment plan for the $500 million of 3.45% senior notes due June 1, 2026.
• Equity Method Investments: Assess the $7 million loss in equity earnings from strategic investments and the potential for future impairment.